NUS vs. NVS

Last updated Apr 1, 2026

Compare and contrast key facts about Nu Skin Enterprises, Inc. (NUS) and Novartis AG (NVS).

Performance

NUS vs. NVS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nu Skin Enterprises, Inc. (NUS) and Novartis AG (NVS). The values are adjusted to include any dividend payments, if applicable.

NUS vs. NVS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NUS Nu Skin Enterprises, Inc.	-23.79%	43.29%	-63.67%	-51.07%	-13.92%	-4.32%	38.67%	-30.98%	-8.32%	46.55%
NVS Novartis AG	14.16%	46.95%	0.02%	16.14%	8.06%	-3.65%	3.34%	13.92%	5.95%	19.42%

Fundamentals

Market Cap NUS : $363.36M NVS : $294.65B
EPS NUS : $3.21 NVS : $7.20
PE Ratio NUS : 2.27 NVS : 21.22
PEG Ratio NUS : 0.01 NVS : 1.43
PS Ratio NUS : 0.24 NVS : 5.29
PB Ratio NUS : 0.45 NVS : 6.39
Total Revenue (TTM) NUS : $1.49B NVS : $56.15B
Gross Profit (TTM) NUS : $1.03B NVS : $41.12B
EBITDA (TTM) NUS : $263.47M NVS : $22.99B

Returns By Period

In the year-to-date period, NUS achieves a -23.79% return, which is significantly lower than NVS's 14.16% return. Over the past 10 years, NUS has underperformed NVS with an annualized return of -12.67%, while NVS has yielded a comparatively higher 11.92% annualized return.

NUS

• 1D: 1.68%
• 1M: -14.15%
• YTD: -23.79%
• 6M: -39.51%
• 1Y: 2.81%
• 3Y*: -40.92%
• 5Y*: -30.33%
• 10Y*: -12.67%

NVS

• 1D: 1.59%
• 1M: -6.65%
• YTD: 14.16%
• 6M: 22.74%
• 1Y: 41.19%
• 3Y*: 22.57%
• 5Y*: 16.43%
• 10Y*: 11.92%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NUS vs. NVS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NUS

NUS Risk / Return Rank: 43
NUS Sharpe Ratio Rank: 43
NUS Sortino Ratio Rank: 42
NUS Omega Ratio Rank: 42
NUS Calmar Ratio Rank: 43
NUS Martin Ratio Rank: 43

NVS

NVS Risk / Return Rank: 89
NVS Sharpe Ratio Rank: 90
NVS Sortino Ratio Rank: 87
NVS Omega Ratio Rank: 85
NVS Calmar Ratio Rank: 90
NVS Martin Ratio Rank: 91

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NUS vs. NVS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nu Skin Enterprises, Inc. (NUS) and Novartis AG (NVS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NUS	NVS	Difference
Sharpe ratio Return per unit of total volatility	0.05	1.91	-1.86
Sortino ratio Return per unit of downside risk	0.50	2.51	-2.01
Omega ratio Gain probability vs. loss probability	1.07	1.33	-0.26
Calmar ratio Return relative to maximum drawdown	0.08	3.70	-3.62
Martin ratio Return relative to average drawdown	0.17	10.89	-10.71
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NUS vs. NVS - Sharpe Ratio Comparison

The current NUS Sharpe Ratio is 0.05, which is lower than the NVS Sharpe Ratio of 1.91. The chart below compares the historical Sharpe Ratios of NUS and NVS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NUS	NVS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.05	1.91	-1.86
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.65	0.89	-1.54
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.26	0.61	-0.87
Sharpe Ratio (All Time) Calculated using the full available price history	-0.05	0.43	-0.48

Correlation

The correlation between NUS and NVS is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NUS vs. NVS - Dividend Comparison

NUS's dividend yield for the trailing twelve months is around 3.30%, more than NVS's 3.12% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
NUS Nu Skin Enterprises, Inc.	3.30%	2.49%	3.48%	8.03%	3.65%	3.00%	2.75%	3.61%	2.38%	2.11%	2.97%	3.69%
NVS Novartis AG	3.12%	2.90%	3.84%	3.44%	3.70%	3.86%	3.22%	3.03%	3.47%	3.24%	3.73%	3.10%

Drawdowns

NUS vs. NVS - Drawdown Comparison

The maximum NUS drawdown since its inception was -94.29%, which is greater than NVS's maximum drawdown of -42.10%. Use the drawdown chart below to compare losses from any high point for NUS and NVS.

Drawdown Indicators

	NUS	NVS	Difference
Max Drawdown Largest peak-to-trough decline	-94.29%	-42.10%	-52.19%
Max Drawdown (1Y) Largest decline over 1 year	-43.92%	-10.76%	-33.16%
Max Drawdown (5Y) Largest decline over 5 years	-89.87%	-20.42%	-69.45%
Max Drawdown (10Y) Largest decline over 10 years	-91.89%	-26.03%	-65.86%
Current Drawdown Current decline from peak	-92.22%	-6.65%	-85.57%
Average Drawdown Average peak-to-trough decline	-47.80%	-10.94%	-36.86%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.65%	3.66%	+15.99%

Volatility

NUS vs. NVS - Volatility Comparison

Nu Skin Enterprises, Inc. (NUS) has a higher volatility of 8.54% compared to Novartis AG (NVS) at 6.36%. This indicates that NUS's price experiences larger fluctuations and is considered to be riskier than NVS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NUS	NVS	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.54%	6.36%	+2.18%
Volatility (6M) Calculated over the trailing 6-month period	37.25%	14.77%	+22.48%
Volatility (1Y) Calculated over the trailing 1-year period	57.62%	21.66%	+35.96%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	46.70%	18.51%	+28.19%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	49.03%	19.55%	+29.48%

Financials

NUS vs. NVS - Profitability Comparison

The chart below illustrates the profitability comparison between Nu Skin Enterprises, Inc. and Novartis AG over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

NUS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Nu Skin Enterprises, Inc. reported a gross profit of 261.98M and revenue of 370.32M. Therefore, the gross margin over that period was 70.7%.

NVS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Novartis AG reported a gross profit of 8.40B and revenue of 13.33B. Therefore, the gross margin over that period was 63.0%.

NUS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Nu Skin Enterprises, Inc. reported an operating income of 23.24M and revenue of 370.32M, resulting in an operating margin of 6.3%.

NVS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Novartis AG reported an operating income of 3.05B and revenue of 13.33B, resulting in an operating margin of 22.8%.

NUS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Nu Skin Enterprises, Inc. reported a net income of 14.49M and revenue of 370.32M, resulting in a net margin of 3.9%.

NVS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Novartis AG reported a net income of 2.41B and revenue of 13.33B, resulting in a net margin of 18.1%.